CACNA1B (Ca<sub>v</sub>2.2) Overexpression and Its Association with Clinicopathologic Characteristics and Unfavorable Prognosis in Non-Small Cell Lung Cancer

<div>CACNA1B (<svg height="12.0621pt" id="M29" style="vertical-align:-3.2957pt" version="1.1" viewbox="-0.0498162 -8.7664 19.5693 12.0621" width="19.5693pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.013,0,0,-0.013,0,0)"><path d="M614 175C564 76 510 21 408 21C256 21 146 149 146 336C146 488 235 629 402 629C510 629 570 586 597 480L626 488C620 541 614 582 606 638C578 643 510 665 429 665C206 665 44 527 44 316C44 157 153 -15 402 -15C474 -15 558 5 586 11C604 45 629 119 643 165L614 175Z" id="g121-65"></path><glyph.data ascent="989" descent="-360" horiz-adv-x="665" vert-adv-y="665"></glyph.data></g><g transform="matrix(.013,0,0,-0.013,8.762,0)"><path d="M433 39L423 65C413 59 399 54 387 54C370 54 352 69 352 114V299C352 352 342 392 307 422C285 440 255 449 225 449C168 437 102 399 75 379C56 365 44 353 44 339C44 315 69 296 87 296C101 296 111 303 116 319C124 349 133 371 145 385C156 397 171 404 190 404C241 404 275 364 275 291V274C253 256 180 229 120 209C65 190 39 159 39 110C39 47 88 -12 159 -12C189 -12 237 25 277 52C282 35 288 21 301 8C312 -3 333 -12 348 -12L433 39ZM275 84C256 65 221 48 195 48C164 48 124 73 124 124C124 161 146 180 185 198C206 208 254 229 275 240V84Z" id="g121-95"></path><glyph.data ascent="989" descent="-360" horiz-adv-x="439" vert-adv-y="439"></glyph.data></g><g transform="matrix(.0091,0,0,-0.0091,14.523,3.132)"><path d="M487 439H304V409C361 402 367 391 351 344C328 280 297 190 262 110C235 178 192 284 168 353C152 396 153 403 208 409V439H-1V409C54 401 61 394 85 338C133 221 179 111 224 -10H255C312 139 363 260 398 336C426 394 432 401 487 409V439Z" id="g58-116"></path><glyph.data ascent="1007" descent="-369" horiz-adv-x="473" vert-adv-y="473"></glyph.data></g></svg>2.2) mRNA level was significantly higher in NSCLC tumorous tissues than in adjacent nontumorous tissues. CACNA1B (<svg height="12.0621pt" id="M30" style="vertical-align:-3.2957pt" version="1.1" viewbox="-0.0498162 -8.7664 19.5693 12.0621" width="19.5693pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.013,0,0,-0.013,0,0)"><path d="M614 175C564 76 510 21 408 21C256 21 146 149 146 336C146 488 235 629 402 629C510 629 570 586 597 480L626 488C620 541 614 582 606 638C578 643 510 665 429 665C206 665 44 527 44 316C44 157 153 -15 402 -15C474 -15 558 5 586 11C604 45 629 119 643 165L614 175Z" id="g121-65"></path><glyph.data ascent="989" descent="-360" horiz-adv-x="665" vert-adv-y="665"></glyph.data></g><g transform="matrix(.013,0,0,-0.013,8.762,0)"><path d="M433 39L423 65C413 59 399 54 387 54C370 54 352 69 352 114V299C352 352 342 392 307 422C285 440 255 449 225 449C168 437 102 399 75 379C56 365 44 353 44 339C44 315 69 296 87 296C101 296 111 303 116 319C124 349 133 371 145 385C156 397 171 404 190 404C241 404 275 364 275 291V274C253 256 180 229 120 209C65 190 39 159 39 110C39 47 88 -12 159 -12C189 -12 237 25 277 52C282 35 288 21 301 8C312 -3 333 -12 348 -12L433 39ZM275 84C256 65 221 48 195 48C164 48 124 73 124 124C124 161 146 180 185 198C206 208 254 229 275 240V84Z" id="g121-95"></path><glyph.data ascent="989" descent="-360" horiz-adv-x="439" vert-adv-y="439"></glyph.data></g><g transform="matrix(.0091,0,0,-0.0091,14.523,3.132)"><path d="M487 439H304V409C361 402 367 391 351 344C328 280 297 190 262 110C235 178 192 284 168 353C152 396 153 403 208 409V439H-1V409C54 401 61 394 85 338C133 221 179 111 224 -10H255C312 139 363 260 398 336C426 394 432 401 487 409V439Z" id="g58-116"></path><glyph.data ascent="1007" descent="-369" horiz-adv-x="473" vert-adv-y="473"></glyph.data></g></svg>2.2) mRNA was determined by qRT-PCR and relative quantification analysis by normalizing to GAPDH mRNA.</div>

Disease Markers

fig1

Figure 1

Figure 1: CACNA1B (Ca<sub>v</sub>2.2) Overexpression and Its Association with Clinicopathologic Characteristics and Unfavorable Prognosis in Non-Small Cell Lung Cancer 

Figure 1 | CACNA1B (Cav2.2) Overexpression and Its Association with Clinicopathologic Characteristics and Unfavorable Prognosis in Non-Small Cell Lung Cancer 